Skip to main content
SpringerLink
Log in

Psoriasis Biologic Agents in Special Populations

  • Chapter
  • First Online:
Biologic Therapy for Psoriasis

Part of the book series: Updates in Clinical Dermatology ((UCD))

  • 524 Accesses

Abstract

Since the advent of biologic treatments for psoriasis in the early 2000s, this class of medicines has proven to be a safe and effective therapeutic option in the treatment of moderate-to-severe psoriasis. Numerous biologic treatment options have been developed in the past 20 years, allowing for tailored treatment regimens for psoriasis in special populations, which will be the focus of this chapter. Specifically, this section will focus on treatment algorithms in the following groups: pregnant and breastfeeding patients, human immunodeficiency virus-positive patients, patients with a history of nonmelanoma skin cancer and lymphoma, patients undergoing surgery, and geriatric patients. Additionally, an upcoming precision medicine tool meant to guide clinicians in selecting biologics for psoriasis treatment will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CD4+:

Cluster of differentiation 4

CI:

Confidence interval

FC:

Fragment, crystallizable

FDA:

Food and Drug Administration

HIV:

Human immunodeficiency virus

IL:

Interleukin

NMSC:

Nonmelanoma skin cancer

NPF:

National Psoriasis Foundation

OR:

Odds ratio

PASI:

Psoriasis Area and Severity Index

PGA:

Physician Global Assessment and Body Surface Area

References

  1. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm. 2004;10(4):318–25. https://doi.org/10.18553/jmcp.2004.10.4.318.

    Article  PubMed  Google Scholar 

  2. Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39–51. https://doi.org/10.2147/BTT.S252578.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–32. https://doi.org/10.1016/j.jaad.2017.10.012.

    Article  PubMed  Google Scholar 

  4. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1–13. https://doi.org/10.1007/s40257-017-0328-3.

    Article  CAS  PubMed  Google Scholar 

  5. Galluzzo M, D’Adamio S, Bianchi L, Talamonti M. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2019;30(1):40–4. https://doi.org/10.1080/09546634.2018.1468066.

    Article  CAS  PubMed  Google Scholar 

  6. Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context. 2020;9. https://doi.org/10.7573/dic.2019-11-6.

  7. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–33. https://doi.org/10.1136/annrheumdis-2017-212196.

    Article  CAS  PubMed  Google Scholar 

  8. Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70(9):1399–407. https://doi.org/10.1002/art.40508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–6. https://doi.org/10.1136/annrheumdis-2017-211384.

    Article  CAS  PubMed  Google Scholar 

  10. Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21–5. https://doi.org/10.1016/j.ijwd.2016.12.003.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Eworuke E, Panucci G, Goulding M, Neuner R, Toh S. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. Pharmacoepidemiol Drug Saf. 2019;28(3):296–304. https://doi.org/10.1002/pds.4695.

    Article  CAS  PubMed  Google Scholar 

  12. Bröms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, et al. Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020;29(3):316–27. https://doi.org/10.1002/pds.4930.

    Article  CAS  PubMed  Google Scholar 

  13. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther. 2017;30(3). https://doi.org/10.1111/dth.12454.

  14. Watson N, Wu K, Farr P, Reynolds NJ, Hampton PJ. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2019;180(1):195–6. https://doi.org/10.1111/bjd.17086.

    Article  CAS  PubMed  Google Scholar 

  15. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11(10):1240.

    PubMed  Google Scholar 

  16. Rocha K, Piccinin MC, Kalache LF, Reichert-Faria A, Silva de Castro CC. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology. 2015;231(2):103–4. https://doi.org/10.1159/000380880.

    Article  PubMed  Google Scholar 

  17. Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30(3):488–90. https://doi.org/10.1111/jdv.12872.

    Article  CAS  PubMed  Google Scholar 

  18. Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol. 2014;55(3):235–6. https://doi.org/10.1111/ajd.12214.

    Article  PubMed  Google Scholar 

  19. MotherToBaby: Ustekinumab (Stelara®) Fact Sheet. https://mothertobaby.org/fact-sheets/ustekinumab-pregnancy/pdf/ (2019). Accessed 27 Nov 2020.

  20. Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–7. https://doi.org/10.1111/bjd.16901.

    Article  CAS  PubMed  Google Scholar 

  21. AstraZeneca I: SILIQTM (brodalumab) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf (2017). Accessed 12 July 2021.

  22. Company ELa: TALTZ (ixekizumab) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf (2016). Accessed 12 July 2021.

  23. Janssen Biotech I: Tremfya™ (guselkumab) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf (2017). Accessed 12 July 2021.

  24. Abbvie I: SKYRIZITM (risankizumab-rzaa) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf (2019). Accessed 12 July 2021.

  25. Sun Pharma I: ILUMYATM (tildrakizumab-asmn) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf#page=10 (2018). Accessed 12 July 2021.

  26. Prevention CfDCa: HIV Basics. https://www.cdc.gov/hiv/basics/statistics.html (2021). Accessed 30 June 2021.

  27. Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291–9. https://doi.org/10.1016/j.jaad.2009.03.047.

    Article  PubMed  Google Scholar 

  28. Fife DJ, Waller JM, Jeffes EW, Koo JY. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. Dermatol Online J. 2007;13(2):4.

    PubMed  Google Scholar 

  29. Armstrong AW: Treatment selection for moderate to severe plaque psoriasis in special populations. https://www.uptodate.com/contents/treatment-selection-for-moderate-to-severe-plaque-psoriasis-in-special-populations#H9475354 (2020). Accessed 14 July 2021.

  30. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.

    Article  PubMed  Google Scholar 

  31. Nicoletta B, Alessandra N, Nevena S, Tolino E, Colapietra D, Claudio M, et al. Management of psoriatic patients in biologic treatment associated with infectious comorbidities. Postepy Dermatol Alergol. 2020;37(3):417–21. https://doi.org/10.5114/ada.2020.96155.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc. 2000;75(10):1093–8. https://doi.org/10.4065/75.10.1093.

    Article  CAS  PubMed  Google Scholar 

  33. Lee ES, Heller MM, Kamangar F, Park KK, Koo JY. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. J Drugs Dermatol. 2012;11(3):413–4.

    CAS  PubMed  Google Scholar 

  34. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008;144(4):453–6. https://doi.org/10.1001/archderm.144.4.453.

    Article  PubMed  Google Scholar 

  35. De Simone C, Perino F, Caldarola G, D’Agostino M, Peris K. Treatment of psoriasis with etanercept in immunocompromised patients: two case reports. J Int Med Res. 2016;44(1 suppl):67–71. https://doi.org/10.1177/0300060515593250.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat. 2012;23(6):398–9. https://doi.org/10.3109/09546634.2011.579085.

    Article  CAS  PubMed  Google Scholar 

  37. Saeki H, Ito T, Hayashi M, Fukuchi O, Umezawa Y, Nobeyama Y, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653–5. https://doi.org/10.1111/jdv.12531.

    Article  CAS  PubMed  Google Scholar 

  38. Lindsey SF, Weiss J, Lee ES, Romanelli P. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. J Drugs Dermatol. 2014;13(7):869–71.

    PubMed  Google Scholar 

  39. Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. J Dermatolog Treat. 2019;30(5):461–5. https://doi.org/10.1080/09546634.2018.1535690.

    Article  CAS  PubMed  Google Scholar 

  40. Bardazzi F, Magnano M, Campanati A, Loconsole F, Carpentieri A, Potenza C, et al. Biologic therapies in HIV-infected patients with psoriasis: an Italian experience. Acta Derm Venereol. 2017;97(8):989–90. https://doi.org/10.2340/00015555-2698.

    Article  PubMed  Google Scholar 

  41. UCB I: CIMZIA (certolizumab pegol) for injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf (2017). Accessed 12 July 2021.

  42. Pangilinan MCG, Sermswan P, Asawanonda P. Use of anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol. 2020;12(2):132–7. https://doi.org/10.1159/000508781.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019;17(6):646–8. https://doi.org/10.1111/ddg.13851.

    Article  PubMed  Google Scholar 

  44. Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:36–46. https://doi.org/10.1111/jdv.12165.

    Article  CAS  PubMed  Google Scholar 

  45. Lee MS, Lin RY, Chang YT, Lai MS. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol. 2012;51(12):1454–60. https://doi.org/10.1111/j.1365-4632.2011.05310.x.

    Article  PubMed  Google Scholar 

  46. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90. https://doi.org/10.1016/j.jaad.2016.07.064.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–201. https://doi.org/10.1038/sj.jid.5700410.

    Article  CAS  PubMed  Google Scholar 

  48. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282–90. https://doi.org/10.1001/jamadermatol.2015.4847.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66(5):731–41. https://doi.org/10.1016/j.jaad.2011.06.011.

    Article  CAS  PubMed  Google Scholar 

  50. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51. https://doi.org/10.1016/j.jaad.2011.06.041.

    Article  CAS  PubMed  Google Scholar 

  51. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54. https://doi.org/10.1111/bjd.12214.

    Article  CAS  PubMed  Google Scholar 

  52. Charakopoulos E, Spyrou I, Viniou NA, Giannakopoulou N, Hatzidavid S, Diamantopoulos PT. A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis. Medicine (Baltimore). 2020;99(21):e20048. https://doi.org/10.1097/md.0000000000020048.

    Article  Google Scholar 

  53. Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63(5):419–35. https://doi.org/10.1007/s00262-014-1523-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14.

    CAS  PubMed  Google Scholar 

  55. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248–56. https://doi.org/10.1038/nri2742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4. https://doi.org/10.1016/j.jaad.2016.03.024.

    Article  CAS  PubMed  Google Scholar 

  57. Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A. Malignancy rates in brodalumab clinical studies for psoriasis. Am J Clin Dermatol. 2020;21(3):421–30. https://doi.org/10.1007/s40257-020-00512-4.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–40.e17. https://doi.org/10.1016/j.jaad.2016.09.026.

    Article  CAS  PubMed  Google Scholar 

  59. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. https://doi.org/10.1016/j.jaad.2016.11.041.

    Article  CAS  PubMed  Google Scholar 

  60. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31. https://doi.org/10.1016/j.jaad.2016.11.042.

    Article  CAS  PubMed  Google Scholar 

  61. Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–17. https://doi.org/10.1111/bjd.18232.

    Article  CAS  PubMed  Google Scholar 

  62. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. https://doi.org/10.1016/s0140-6736(18)31713-6.

    Article  CAS  PubMed  Google Scholar 

  63. Bachelez H, Gordon K, Blauvelt A, Wu J, Sinvhal R, Photowala H, et al. Short- and long-term safety of risankizumab in patients with moderate to-severe psoriasis: an integrated analysis. J Eur Acad Dermatol Venereol. 2019;33:37–8. ISBN/ISSN: 09269959

    Google Scholar 

  64. Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol. 2018;178(1):103–13. https://doi.org/10.1111/bjd.15830.

    Article  CAS  PubMed  Google Scholar 

  65. van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29(4):752–60. https://doi.org/10.1111/jdv.12675.

    Article  CAS  PubMed  Google Scholar 

  66. Food, Administration D. Follow-up to the June 4 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi).

    Google Scholar 

  67. Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018;143(5):1062–71. https://doi.org/10.1002/ijc.31407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50. https://doi.org/10.1016/j.jaad.2010.09.734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276–84. https://doi.org/10.1016/s2468-1253(19)30362-0.

    Article  PubMed  Google Scholar 

  70. Phan C, Sigal ML, Estève E, Reguiai Z, Barthélémy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82. https://doi.org/10.1111/jdv.12850.

    Article  CAS  PubMed  Google Scholar 

  71. Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897–903. https://doi.org/10.1080/14712598.2018.1504016.

    Article  CAS  PubMed  Google Scholar 

  72. Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–45. https://doi.org/10.1016/j.jaad.2010.05.014.

    Article  PubMed  Google Scholar 

  73. Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(9):1736–43.e4. https://doi.org/10.1016/j.cgh.2018.12.032.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974–80. https://doi.org/10.1111/1346-8138.12653.

    Article  CAS  PubMed  Google Scholar 

  75. Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564–6. https://doi.org/10.1111/ced.12850.

    Article  CAS  PubMed  Google Scholar 

  76. Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. https://doi.org/10.2340/00015555-3678.

    Article  CAS  PubMed  Google Scholar 

  77. Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–44. https://doi.org/10.1007/s40266-018-0520-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Megna M, Camela E, Cinelli E, Fabbrocini G. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45(7):848–52. https://doi.org/10.1111/ced.14258.

    Article  CAS  PubMed  Google Scholar 

  79. Ricceri F, Pescitelli L, Lazzeri L, Di Cesare A, Prignano F. First case of secukinumab successful therapy in a very elderly psoriatic patient. Dermatol Ther. 2018;31(5):e12668. https://doi.org/10.1111/dth.12668.

    Article  CAS  PubMed  Google Scholar 

  80. Megna M, Cinelli E, Balato A, Gallo L, Fabbrocini G. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol. 2020;34(3):e152–e3. https://doi.org/10.1111/jdv.16063.

    Article  CAS  PubMed  Google Scholar 

  81. Khalid U, Ahlehoff O, Gislason GH, Kristensen SL, Skov L, Torp-Pedersen C, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743–8. https://doi.org/10.1002/ejhf.113.

    Article  PubMed  Google Scholar 

  82. Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168–77. https://doi.org/10.1016/j.jaad.2013.09.020.

    Article  PubMed  Google Scholar 

  83. Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668. https://doi.org/10.3389/fimmu.2018.01668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Boyer JF, Jamard B, El Mahou S, Laroche M, Mazières B, Cantagrel A, et al. New-onset acute heart failure and ventricular tachycardia after therapy with a tumor necrosis factor antagonist. Clin Exp Rheumatol. 2005;23(2):274–5.

    CAS  PubMed  Google Scholar 

  85. Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermosifiliogr. 2012;103(10):853–62. https://doi.org/10.1016/j.adengl.2012.02.004.

    Article  PubMed  Google Scholar 

  86. Administration FaD: FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNF alpha) blockers now include warnings about infection with Legionella and Listeria bacteria. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-drug-labels-tumor-necrosis-factor-alpha-tnfa-blockers-now-include (2011). Accessed 1 July 2021.

  87. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448–56. https://doi.org/10.1016/j.jaad.2009.09.040.

    Article  CAS  PubMed  Google Scholar 

  88. Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86. https://doi.org/10.1177/1203475419897578.

    Article  PubMed  Google Scholar 

  89. Chiricozzi A, Zangrilli A, Bavetta M, Bianchi L, Chimenti S, Saraceno R. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol. 2017;31(2):304–11. https://doi.org/10.1111/jdv.13771.

    Article  CAS  PubMed  Google Scholar 

  90. Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225(4):312–9. https://doi.org/10.1159/000345623.

    Article  CAS  PubMed  Google Scholar 

  91. Chiricozzi A, Pavlidis A, Dattola A, Bianchi L, Chimenti MS, Fida M, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15(11):1459–62. https://doi.org/10.1080/14740338.2016.1226279.

    Article  CAS  PubMed  Google Scholar 

  92. Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33(1):143–6. https://doi.org/10.1111/jdv.15139.

    Article  CAS  PubMed  Google Scholar 

  93. Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7. https://doi.org/10.2340/00015555-1719.

    Article  PubMed  Google Scholar 

  94. Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat. 2019;30(7):668–73. https://doi.org/10.1080/09546634.2018.1544413.

    Article  CAS  PubMed  Google Scholar 

  95. Goodman SM. Rheumatoid arthritis: perioperative management of biologics and DMARDs. Semin Arthritis Rheum. 2015;44(6):627–32. https://doi.org/10.1016/j.semarthrit.2015.01.008.

    Article  CAS  PubMed  Google Scholar 

  96. Argollo MC, Kotze PG, Spinelli A, Gomes TNF, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32-33:79–87. https://doi.org/10.1016/j.bpg.2018.05.014.

    Article  PubMed  Google Scholar 

  97. Lightner AL, McKenna NP, Tse CS, Hyman N, Smith R, Ovsepyan G, et al. Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohns Colitis. 2018;12(4):402–7. https://doi.org/10.1093/ecco-jcc/jjx163.

    Article  PubMed  Google Scholar 

  98. Hernandez C, Emer J, Robinson JK. Perioperative management of medications for psoriasis and psoriatic arthritis: a review for the dermasurgeon. Dermatol Surg. 2008;34(4):446–59. https://doi.org/10.1111/j.1524-4725.2007.34091.x.

    Article  CAS  PubMed  Google Scholar 

  99. Novartis I: COSENTYX® (secukinumab) injection, for subcutaneous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf (2015). Accessed 1 Oct 2020.

  100. Nguyen ED, Gabel CK, Kroshinsky D. Assessing the incidence of skin and soft tissue infection in patients on biologics. J Am Acad Dermatol. 2020; https://doi.org/10.1016/j.jaad.2020.03.128.

  101. Novello M, Stocchi L, Holubar S, Shawki S, Lipman J, Gorgun E, et al. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis. Int J Color Dis. 2019;34(3):451–7. https://doi.org/10.1007/s00384-018-3212-6.

    Article  Google Scholar 

  102. Fabiano A, De Simone C, Gisondi P, Piaserico S, Lasagni C, Pellacani G, et al. Management of patients with psoriasis treated with biological drugs needing a surgical treatment. Drug Dev Res. 2014;75 Suppl 1:S24–6. https://doi.org/10.1002/ddr.21189.

    Article  CAS  PubMed  Google Scholar 

  103. Bakkour W, Purssell H, Chinoy H, Griffiths CE, Warren RB. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J Eur Acad Dermatol Venereol. 2016;30(1):86–91. https://doi.org/10.1111/jdv.12997.

    Article  CAS  PubMed  Google Scholar 

  104. Galiano Mejías S, Carretero G, Ferrandiz C, Vanaclocha F, Daudén E, Gómez-García FJ, et al. Management of biologic therapy in moderate to severe psoriasis in surgical patients: data from the Spanish Biobadaderm registry. Actas Dermosifiliogr. 2017;108(1):52–8. https://doi.org/10.1016/j.ad.2016.08.003.

    Article  PubMed  Google Scholar 

  105. Reinstadler A, Mau N, Bhutani T, Talkin B, Yamauchi P, Chiu M, et al. Perioperative use of anti-tumor necrosis factor-alfa agents. J Am Acad Dermatol. 2010;62(1):154–5. https://doi.org/10.1016/j.jaad.2009.04.039.

    Article  CAS  PubMed  Google Scholar 

  106. Kawakami H, Matsumoto Y, Abe N, Katori Y, Takahashi K, Tsuboi R, et al. Perioperative management of tumor necrosis factor-alpha blocker-treated psoriatic patients: case reports and review. J Dermatol. 2016;43(2):190–3. https://doi.org/10.1111/1346-8138.13047.

    Article  PubMed  Google Scholar 

  107. Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, et al. From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75(4):798–805.e7. https://doi.org/10.1016/j.jaad.2016.06.014.

    Article  PubMed  Google Scholar 

  108. Afifi L, Shankle L, Armstrong AW, Boas M, Bridges A, Chiguil V, et al. National Psoriasis Foundation priorities for patient-centered research: proceedings from the 2016 conference. J Psoriasis Psoriatic Arthritis. 2017;2(3):73–80. https://doi.org/10.1177/247553031700200307.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Bell S, Merola JF, Webster DE, Pennington SR, Liao W, Ogdie A, et al. Aiming for cure and preventive initiatives in psoriatic disease: building synergy at NPF, GRAPPA, and PPACMAN. Curr Rheumatol Rep. 2020;22(11):78. https://doi.org/10.1007/s11926-020-00958-9.

    Article  PubMed  Google Scholar 

  110. MINDERA: psoriasis: a chronic disease. https://www.minderadx.com/psoriasis/ (2021). Accessed 11 July 2021.

Download references

Author information

Authors and Affiliations

  1. College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA

    Akshitha Thatiparthi

  2. School of Medicine, University of California, Riverside, CA, USA

    Amylee Martin

  3. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Jeffrey Liu

  4. Icahn School of Medicine at Mount Sinai, New York City, NY, USA

    George Han

  5. Dermatology Research and Education Foundation, Irvine, CA, USA

    Jashin J. Wu

Authors
  1. Akshitha Thatiparthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amylee Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA

    Nicholas Brownstone

  2. Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA

    Tina Bhutani

  3. Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, CA, USA

    Wilson Liao

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thatiparthi, A., Martin, A., Liu, J., Han, G., Wu, J.J. (2022). Psoriasis Biologic Agents in Special Populations. In: Brownstone, N., Bhutani, T., Liao, W. (eds) Biologic Therapy for Psoriasis. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-92938-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-92938-1_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-92937-4

  • Online ISBN: 978-3-030-92938-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation